Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 222Carcinoma, Renal Cell 84Liver Neoplasms 68Neoplasms 53Leukemia, Myeloid, Acute 37Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 29Melanoma 24Kidney Neoplasms 22Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Thyroid Neoplasms 13Recurrence 13Glioblastoma 13Colorectal Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

carotuximab 1baricitinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Liver Cell × Sorafenib × Clear all
NCT01306058 2019-01-23

Sorafenib and TRC105 in Hepatocellular Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 32 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Liver Neoplasms, Experimental, Adenoma, Liver Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡